Why Is RECURSION PHARMACEUT A (RXRX) Stock Moving Today?

Recursion Pharmaceuticals (RXRX) shares fell 8.66% to close at $3.80. The decline followed the company’s announcement of a $200 million common stock offering, which weighed on the stock despite a recent positive catalyst from its partnership with Sanofi.

What Happened

Recursion Pharmaceuticals launched a $200 million equity offering, pricing 61,540,000 shares of Class A common stock at $3.25 per share. The move was intended to strengthen the company’s balance sheet and advance its pipeline. This announcement came shortly after the company reported that Sanofi selected its first drug development candidate under their collaboration, triggering a $10 million milestone payment.

The Sanofi news had initially driven the stock up 15.4% on Thursday. However, the subsequent equity raise and a rating of Hold from analysts citing limited near-term catalysts contributed to the current pullback. Morgan Stanley raised its price target to $5.90 from $5.30, while other analysts maintained a Hold stance on the REC-4881 program update.

What The Data Shows

The stock opened at $4.16 and hit a session high of $4.18 at 9:30 AM ET before dropping to a low of $3.74 at 10:25 AM ET. Trading volume reached 12.6 million shares, which is 0.6 times the three-month daily average. The company has a market cap of $2.0 billion and is unprofitable, with trailing twelve-month earnings per share of negative $1.02. Revenue declined 15.1% over the same period.

Over the last 8 sessions, the stock moved down 7.2% from $4.63 to $4.30. The 52-week range is $2.77 to $7.18. Recent insider activity includes five sells totaling $644,000 in the last 90 days, with no buys recorded. Directors Blake Borgeson and Robert Hershberg sold shares on October 6, 2026, while CEO Najat Khan sold on September 8, 2026.

What To Watch

Investors will monitor the completion of the $200 million offering and the potential start of Phase 1 trials in 2027 for the Sanofi-selected candidate. The stock’s reaction to the new share issuance and any further updates on the REC-4881 program will be key factors in the near term.

Why is RXRX stock moving today?

RECURSION PHARMACEUT A (RXRX) is drawing unusual attention today. Our newswire has captured 1 story on RXRX across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "RXRX, Recursion Pharm | IBD Stock Checkup" (Investors.com).

Is RXRX a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RXRX coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.